-
Mashup Score: 9News Details - 10 month(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 125News Details - 10 month(s) ago
Bagsværd, Denmark, 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACEs) over a period of up to five years. The trial enrolled 17,604 adults aged 45 years or older with overweight or obesity and established cardiovascular disease (CVD) with no prior history of
Source: www.novonordisk.comCategories: Expert Picks, Latest HeadlinesTweet-
Major Breaking News: A once weekly injection of of obesity drug #Semaglutide reduces the risk of major adverse cardiovascular events by 20% in adults who are overweight or obese in the SELECT trial https://t.co/s4c7W8B5Qn
-
HUGE result! SELECT RCT of semaglutide reduces composite of heart attack, stroke, & cardiovascular death in patients w/o diabetes but w/ history of CVD & overwt/obesity Need to see full report, but likely this will be std secondary prevention tx https://t.co/xQ8v4kMPQ8 https://t.co/aa5z3P0loR
-
the SELECT randomised trial of Ozempic/semaglutide v placebo reduced Heart attacks/strokes/CV death by 20% in non diabetic adults with higher BMI & established cardiovascular disease (CVD) we may be giving all overweight CAD patients GLP1s @PCCS_UK https://t.co/byfED5AC8W
-
-
Mashup Score: 4Changing Diabetes in Children - 3 year(s) ago
Our Changing Diabetes in Children programme (CDiC) is changing the future for children with type 1 diabetes in low and middle income countries.
Source: www.novonordisk.comCategories: Latest Headlines, PediatricsTweet-
#ISPAD is happy to have been part of the #ChangingDiabetesInChildren #Hackathon this past weekend, hacking #DigitalHealth innovations for #Type1Diabetes. More details to come and visit https://t.co/l1PypEW10Y to learn more! @NovoNordisk @Roche @HarvardChanSPH @mithackmed https://t.co/3vL5eeZCKf
-
-
Mashup Score: 0Changing Diabetes in Children - 3 year(s) ago
Our Changing Diabetes in Children programme (CDiC) is changing the future for children with type 1 diabetes in low and middle income countries.
Source: www.novonordisk.comCategories: Latest Headlines, PediatricsTweet-
#Type1Diabetes requires a high level of patient knowledge. Together with #ChangingDiabetesinChildren, we’ve developed patient education materials to support children and youth like Matthewos. The materials are available in 5 languages for download here: https://t.co/3he3TaefBp https://t.co/6s2q2J3xPG
-
-
Mashup Score: 10News Details - 3 year(s) ago
Bagsværd , De n mark, 4 June 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy™ is indicated as…
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
MAJOR NEWS: FDA approves #semaglutide 2.4 mg as the first and only once-weekly GLP-1 therapy for weight management Average weight loss 33 pounds, 5 inches off your waistline https://t.co/0yBlFv2sVp
-
SELECT trial: Among 17k w overweight/obesity (BMI >27) & CVD but w/o diabetes, semaglutide 2.4mg sc v placebo led to 20% reduction in MACE https://t.co/yiQRvpxv3W @novonordisk